Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here is the first podcast of what we plan will be an ongoing series of round table discussions with cancer experts about real case scenarios and how we make decisions in practice. My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical oncologist and Director of Hematology/Oncology at Oregon Health & Science University in Portland.
The first case we discussed is a relatively young Asian never-smoking woman with an advanced lung adenocarcinoma, focusing first on the changing standards for sending tissue for molecular testing, as well as the limitations of that. Here is the video version, audio, transcript, and associated figures.
[powerpress]
round-table-laskin-sandler-never-smoker-mutn-testing-audio-podcast
round-table-laskin-sandler-never-smoker-mutn-testing-transcript
round-table-laskin-sandler-never-smoker-mutn-testing-figures
The case continues with the next podcast, discussing first-line chemotherapy-based treatment options and maintenance therapy. Look for that next week.
I've completed several initial podcasts with colleagues from around the country just over the last few weeks, using largely my own cases. However, as I mentioned in an earlier post, we are happy to consider your own cases and questions if you would like to submit them and have questions that are timely and potentially relevant to a broad audience in the cancer community. So if you're interested, please e-mail a brief synopsis and perhaps your central question(s) to west@cancergrace.org for consideration.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.